In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections | Zendy

Stephanie Noviello | Zendy; Sophie Magnet | Zendy; Stephen Hawser | Zendy; David B. Huang | Zendy

Open Access

In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections

Author(s) -

Stephanie Noviello,

Sophie Magnet,

Stephen Hawser,

David B. Huang

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02239-18

Subject(s) - microbiology and biotechnology , antibiotics , staphylococcus aureus , streptococcus anginosus , biology , streptococcus , antibacterial agent , skin infection , trimethoprim , streptococcaceae , bacteria , medicine , genetics

Iclaprim, a selective bacterial dihydrofolate reductase inhibitor, and other antibiotics were tested against Gram-positive isolates from two phase 3 studies of acute bacterial skin and skin structure infections (ABSSSIs) (REVIVE-1 and -2). Seven hundred ninety baseline isolates, includingStaphylococcus aureus , β-hemolytic streptococci, andStreptococcus anginosus group, underwent antibacterial susceptibility testing.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research